Journal
JOURNAL OF GASTROENTEROLOGY
Volume 55, Issue 1, Pages 4-14Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s00535-019-01618-1
Keywords
Crohn's disease; Ulcerative colitis; Treatment; Bacteria; Live biotherapeutic products
Categories
Funding
- NIDDK NIH HHS [P01 DK094779] Funding Source: Medline
- NIEHS NIH HHS [P30 ES010126] Funding Source: Medline
Ask authors/readers for more resources
Altered intestinal microbial composition (dysbiosis) and metabolic products activate aggressive mucosal immune responses that mediate inflammatory bowel diseases (IBD). This dysbiosis impairs the function of regulatory immune cells, which normally promote mucosal homeostasis. Normalizing and maintaining regulatory immune cell function by correcting dysbiosis provides a promising approach to treat IBD patients. However, existing microbe-targeted therapies, including antibiotics, prebiotics, probiotics, and fecal microbial transplantation, provide variable outcomes that are not optimal for current clinical application. This review discusses recent progress in understanding the dysbiosis of IBD and the basis for therapeutic restoration of homeostatic immune function by manipulating an individual patient's microbiota composition and function. We believe that identifying more precise therapeutic targets and developing appropriate rapid diagnostic tools will guide more effective and safer microbe-based induction and maintenance treatments for IBD patients that can be applied in a personalized manner.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available